Literature DB >> 26082097

Neurological adverse effects of methylphenidate may be misdiagnosed as meningoencephalitis.

Luke Blagdon Snell1, Dinkar Bakshi2.   

Abstract

We present a case of adverse neurological effects of methylphenidate therapy for attention deficit and hyperactivity disorder (ADHD). A 7-year-old boy presented to the emergency department (ED) having developed ataxic gait, orofacial dyskinesias and choreoathetosis of the limbs. The results of all blood investigations, EEG and CT scan of the head were unremarkable. Subsequently, a detailed history revealed he was being treated for ADHD, being started on methylphenidate in the past 3 months. Discontinuation of methylphenidate led to significant and rapid amelioration of neurological adverse effects. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26082097      PMCID： PMC4480092          DOI： 10.1136/bcr-2014-207796

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  17 in total

1.  A Case Report of Methylphenidate-Induced Dyskinesia.

Authors:  Thomas W. Heinrich
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-08

2.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

3.  Determination of methylphenidate and ritalinic acid in blood, plasma and oral fluid from adolescents and adults using protein precipitation and liquid chromatography tandem mass spectrometry--a method applied on clinical and forensic investigations.

Authors:  Martin Josefsson; Irene Rydberg
Journal:  J Pharm Biomed Anal       Date:  2011-03-11       Impact factor: 3.935

4.  Dextroamphetamine-sulfate-induced dyskinesias.

Authors:  R H Mattson; J R Calverley
Journal:  JAMA       Date:  1968-04-29       Impact factor: 56.272

5.  Methylphenidate-induced choreoathetosis.

Authors:  I Extein
Journal:  Am J Psychiatry       Date:  1978-02       Impact factor: 18.112

6.  Adverse response to methylphenidate in combination with valproic acid.

Authors:  L Gara; W Roberts
Journal:  J Child Adolesc Psychopharmacol       Date:  2000       Impact factor: 2.576

7.  The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.

Authors:  Ingrid Schubert; Ingrid Köster; Gerd Lehmkuhl
Journal:  Dtsch Arztebl Int       Date:  2010-09-10       Impact factor: 5.594

8.  Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment.

Authors:  D F Connor; S Benjamin; K R Ozbayrak
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1995-11       Impact factor: 8.829

9.  Methylphenidate-induced orofacial and extremity dyskinesia.

Authors:  Judit Balázs; Márta Besnyo; Júlia Gádoros
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-06       Impact factor: 2.576

10.  Regional brain differences in cortical thickness, surface area and subcortical volume in individuals with Williams syndrome.

Authors:  Shashwath A Meda; Jennifer R Pryweller; Tricia A Thornton-Wells
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.